– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – "With this license agreement, we have now preserved the majority of LINZESS patent ...

– New patents expected to provide coverage for 72 mcg dose into 2031 – BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and ...

Ironwood Pharmaceuticals (IRWD +0.3%) and U.S. commercialization partner Allergan (AGN-0.6%) announce that the FDA has accepted for review their supplemental New Drug Application (sNDA) seeking ...

Ironwood and Allergan have reached an agreement with Teva resolving patent litigation brought in response to Teva seeking approval to market generic versions of 145 mcg and 290 mcg Linzess ...

Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...

The FINANCIAL — Astellas Pharma Inc. announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS Tablets for irritable bowel syndrome with constipation) (“IBS-C”) in Japan on ...

Ironwood Pharmaceuticals has big plans to become a major player in biopharma, but sales of its constipation drug Linzess will need to keep growing if Ironwood is going to execute on those plans.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent ...

* IRONWOOD PHARMACEUTICALS INC - NEW PATENTS EXPECTED TO PROVIDE COVERAGE FOR 72 MCG DOSE INTO 2031 Source text for Eikon: Further company coverage: ...